Clinical trial · Observational
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma
NCT00003863CI-TRIAL-00022866completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Determination of genetic markers for aggressive non-Hodgkin's lymphoma may help identify patients with this disease and help predict the outcome of treatment. PURPOSE: Diagnostic study to determine the genetic markers in patients who have aggressive non-Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| comparative genomic hybridization | Genetic | — | UNRESOLVED |
| cytogenetic analysis | Genetic | — | UNRESOLVED |
| fluorescence in situ hybridization | Genetic | — | UNRESOLVED |
| gene rearrangement analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission. Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
- interventionNames
- Genetic: comparative genomic hybridization
- Genetic: cytogenetic analysis
- Genetic: fluorescence in situ hybridization
- Genetic: gene rearrangement analysis
Primary outcomes (1)
- measure
- response to therapy
- timeFrame
- Up to 5 years
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven aggressive non-Hodgkin's lymphoma and registered to front-line CALGB protocols (e.g, CLB-59903, 59909, 10002, and 50103) * Diffuse small cleaved cell lymphoma * Diffuse mixed small and large cell lymphoma * Diffuse large cell lymphoma * Diffuse large cell immunoblastic lymphoma * Small noncleaved cell lymphoma * Mantle cell lymphoma OR * Previously entered on similar curative CALGB protocols (CLB-8852, CLB-8854, and CLB-9351) with blocks or unstained slides of initial diagnosis available PATIENT CHARACTERISTICS: Age: * 18 years and older
References
Publications (0)
Data not yet available
No reference posted for this study.